Poly Adenosine Diphosphate Ribose Polymerase Market Outlook, Key Financials, Segmental Revenue and Geographical Revenue till 2027
SEATTLE, April 09, 2021, (PHARMIWEB) — Poly adenosine diphosphate ribose polymerase (PARP) is a family of 17 enzymes that combine several (poly) units of ADP-ribose in a chain and transfer them to the target proteins. These proteins aid in restoring the damage in DNA caused due to various factors such as exposure to UV rays, radiation, anti-cancer drugs or other substances in the environment. PARP inhibitors aid in blocking the enzyme important for the repair of single stranded breaks in DNA that effectively destroy cancer cells.
These inhibitors play an effective role in current cancer-combating strategies owing to their effectiveness in eliminating cancer cells compared to existing ovarian cancer treatments. For instance, drugs such as Talazoparib and Veliparib indicated for treatment of ovarian cancer are undergoing phase III clinical trials. Such research and development activities are key factors contributing to the global poly adenosine diphosphate ribose polymerase market growth.
A sample of this report is available upon request @ https://www.coherentmarketinsights.com/insight/request-sample/2029
Poly Adenosine Diphosphate Ribose Polymerase Market Drivers
High prevalence of various cancer types is contributing to growth of the global poly adenosine diphosphate ribose polymerase market. Cancer is one of the most prevalent fatal chronic disorders with a high mortality rate due to its invasive nature and prolonged duration of disease. According to the American Cancer Society (ASC), around 22,240 women were diagnosed with ovarian cancer, and around 14,070 deaths were caused by the disease in 2018.
Furthermore, introduction of new drugs has propelled the poly adenosine diphosphate ribose polymerase market growth. For instance, the U.S. Food & Drug Administration approved 3 PARP inhibitors—Olaparib, Rucaparib, and Niraparib. These drugs are potential alternatives that aid in treatment of ovarian and other cancers.
Moreover, combination of these PARP inhibitors with other therapies such as monoclonal antibodies is undergoing research. For instance, in May 2018, TESARO, Inc., an oncology-focused biopharmaceutical company, announced a collaboration with Genentech, a member of the Roche Group, to evaluate the combination of the PD-L1 antibody, Atezolizumab (TECENTRIQ), the MEK inhibitor cobimetinib (COTELLIC), and TESARO’s PARP inhibitor ZEJULA (Niraparib) in patients with platinum-sensitive ovarian cancer. In April 6, 2018, the U.S. Food and Drug Administration (FDA) approved Rubraca (rucaparib) tablets, manufactured by Clovis Oncology Inc., for treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in adult patients.
Moreover, a robust pipeline of poly adenosine diphosphate ribose polymerase inhibitors is contributing to the market growth. For instance, the Veliparib and Talazoparib drugs by AbbVie and Pfizer Inc. are in phase 3 clinical trials. Furthermore, these drugs are expected to effectively treat diseases other than ovarian cancer. Talazoparib developed by Pfizer Inc., is in phase 3 clinical trials for treatment of prostate cancer.
However, various side effects such as possibility of myelodysplastic syndrome or acute myeloid leukemia due to Lynparza (Olaparib), resistance to PARP inhibitors, and regulatory challenges are some of the factors that are expected to hamper the poly adenosine diphosphate ribose polymerase market growth.
Poly Adenosine Diphosphate Ribose Polymerase Market Regional Insights
North America and Europe markets are expected to witness significant growth over the forecast period. High incidence of various types of cancer in these regions is expected to facilitate growth of the market. For instance, in 2018, according to American Cancer Society (ASC), around 164,690 new cases are expected to be diagnosed with prostate cancer.
New product launches and a robust pipeline of PARP inhibitors is expected to boost the growth of the North America, and Europe PARP inhibitors markets over the forecast period. For instance, Clovis Oncology launched Rubraca (Rucaparib) in 2016, and Tesaro, Inc. launched Zejula (Niraparib) in 2017. Moreover, Lynparza (Olaparib) manufactured by AstraZeneca Plc. was approved by the U.S. Food & Drug Administration for treatment of germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer in January 2018.
Poly Adenosine Diphosphate Ribose Polymerase Market Key Player
Key players operating in the poly adenosine diphosphate ribose polymerase market include Tesaro Inc., Clovis Oncology, AstraZeneca, Pfizer, Inc., and AbbVie Inc.
Access insightful study with over 150+ pages, list of tables & figures, profiling 20+ companies.
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2029
Poly Adenosine Diphosphate Ribose Polymerase Market Taxonomy
The global poly adenosine diphosphate ribose polymerase market is segmented on the basis of drug, cancer type, distribution channel, and region.
By Drug –
By Cancer Type –
- Prostate Cancer
- Ovarian Cancer
By Distribution Channel –
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region –
- North America
- Asia Pacific
- Latin America
- Middle East
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire